Evotec

EVT.DE Small Cap

Healthcare · Drug Manufacturers - Specialty & Generic

Updated: Apr 5, 2026, 17:43 UTC

€4.50

+1.03% today

52W: €4.00 – €8.57

52W Low: €4.00 Position: 11.1% 52W High: €8.57

🔗 Compare Brokers

Key Metrics

P/E Ratio

—

Price-to-Earnings

Forward P/E

—

Forward Price/Earnings

P/S Ratio

1.06x

Price-to-Sales

EV/EBITDA

80569.11x

Enterprise Value/EBITDA

Div. Yield

—

Annual dividend yield

Market Cap

$800.4M

Market Capitalization

Revenue Growth

-11.4%

YoY Revenue Growth

Profit Margin

-21.02%

Net profit margin

ROE

-17.98%

Return on Equity

Beta

1.24

Market sensitivity

Short Interest

—

% of float sold short

Avg. Volume

814,905

Average daily volume

Valuation Analysis

Signal

N/A

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

Buy

6 analysts

Avg. Price Target

€6.92

+53.6% upside

Target Range

€4.40 – €10.00

About the Company

Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic disease, and rare diseases; central nervous system (CNS) and cardiometabolic diseases; and animal and women health. The company has collaboration agreements with Mass General Brigham and Joslin Diabetes Center focusing on cardiometabolic diseases; BMS antiviral; Novo Nordisk cell therapy; University of Oxford; German Cancer Research

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic Country: Germany Employees: 4,788 Exchange: GER